MedicaidPrior AuthMedium impact
Papzimeos™ (zopapogene imadenovec-drba) (Revised)
Humana·IN · Genetics, Oncology·Medicaid
We identified it
Jul 21, 2026
Summary
This is a new Prior Authorization policy for Papzimeos™ (zopapogene imadenovec-drba), a gene therapy treatment, effective for Medicaid-Indiana members. The policy establishes authorization requirements before claims can be submitted for this service.
Action Required
Billing team must obtain prior authorization from Humana Medicaid-Indiana before submitting any claims for Papzimeos™ (zopapogene imadenovec-drba). Access the policy documentation at https://dctm.humana.com/Mentor/Web/v.aspx?objectID=090009298a584800 to review specific authorization requirements, medical necessity criteria, and documentation needed. Update internal protocols to flag all Papzimeos™ claims for pre-authorization review. Claims submitted without prior authorization will be denied. Communicate requirements to all relevant clinical staff and ensure encounter documentation includes medical necessity justification.